You are here: Industry Insights > Glenmark

News List

Glenmark announces top-line results from Phase 3 clinical trial of favipiravir for COVID-19 treatment expresspharma
July 23, 2020
The study evaluated the efficacy and safety of favipiravir plus standard supportive care, versus standard supportive care alone, in mild to moderate patients of COVID-19.
FabiFlu more affordable than other drugs: Glenmark to DCGI expresspharma
July 22, 2020
The company also sends its justifications and clarifications to allegations of false claims about FabiFlu’s use for COVID-19 patients.
DCGI queries pharma company on its claim of FabiFlu use for COVID-19 patients with comorbidities expresspharma
July 21, 2020
As per statement by the Glenmark and media reports, the DCGI had accelerated the process for clinical trials and reviews considering the pandemic situation, unmet medical conditions and unavailability of specific therapeutic management against COVID-19...
Glenmark launches hypertension awareness symbol, endorsed by API and HSI expresspharma
July 20, 2020
Glenmark Pharmaceuticals has launched the world’s first hypertension awareness symbol, in collaboration with the Association of Physicians of India (API) and Hypertension Society of India (HSI).
Glenmark Pharma cuts price of COVID-19 drug by 27 pc to Rs 75/tablet expresspharma
July 14, 2020
Glenmark Pharmaceuticals had launched FabiFlu last month at a price of Rs 103 per tablet.
Glenmark’s consolidated revenue rises to Rs 27,674.89 million for Q4 FY 2019-20 expresspharma
June 28, 2020
Glenmark Pharmaceuticals, a research-led global integrated pharmaceutical company announced its financial results for the fourth quarter and year ended March 31, 2020.
Glenmark set to get manufacturing and marketing approval for favipiravir expresspharma
June 22, 2020
Sources inform that SEC has recommended the grant of permission, along with some recommendations, the company plans to launch its product early next week.
Glenmark receives ANDA approval for Fingolimod Capsules expresspharma
June 19, 2020
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (US FDA) for Fingolimod Capsules, 0.5 mg, the generic version of Gilenya Capsules, 0.5 mg, of Novartis Pharmaceuticals.
Glenmark Begins Phase III Trial of Anti-Viral Combo in COVID-19 contractpharma
May 27, 2020
To test the combined efficacy of two antiviral drugs Favipiravir and Umifenovir as a potential COVID-19 treatment.
Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India expresspharma
May 26, 2020
Glenmark is the first company in India to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page